Roivant Sciences Ltd
ROIV
Company Profile
Business description
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Contact
50 Broadway
7th Floor
LondonSW1H 0BD
GBRT: +44 2074003347
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
750
Stocks News & Analysis
stocks
Chart of the Week: AI proving a threat to company moats
The latest insights on AI from our equity research team.
stocks
ASX coal miners will benefit from higher prices
Middle East conflict pushes coal prices higher.
stocks
Nvidia earnings: Another stellar quarter with no signs of a slowdown
We think Nvidia stock is moderately undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,706.30 | 5.50 | -0.06% |
| CAC 40 | 7,969.88 | 4.61 | -0.06% |
| DAX 40 | 23,502.25 | 228.67 | -0.96% |
| Dow JONES (US) | 46,199.62 | 793.64 | -1.69% |
| FTSE 100 | 10,305.29 | 98.31 | -0.94% |
| HKSE | 25,648.77 | 376.65 | -1.45% |
| NASDAQ | 22,164.37 | 315.16 | -1.40% |
| Nikkei 225 | 53,875.94 | 1,363.46 | -2.47% |
| NZX 50 Index | 13,068.60 | 247.00 | -1.85% |
| S&P 500 | 6,626.82 | 89.27 | -1.33% |
| S&P/ASX 200 | 8,513.00 | 7.60 | 0.09% |
| SSE Composite Index | 4,022.30 | 40.69 | -1.00% |